Kalos is developing drugs based on a platform of short amino acids creating therapeutic approaches for orphan, unmet and rare medical conditions. This technology adapts the mechanisms that limit and control remodeling of the heart to control and slow the growth of tumors.

The 2018 U.S. incidence of pancreatic cancer is estimated to be 55,440 (3% of all cancer cases) with annual estimated deaths of 44,330 (7% of all cancer deaths). Kalos has received U.S. and E.U. patents for KTH-222 covering composition of matter, pharmaceutical compositions and method of use as drug treatments for proliferative disorders. The company has also received Orphan Drug Designation for KTH-222 in pancreatic cancer. Kalos has made the strategic decision to focus on research and development activities and will rely on partners with proven capabilities to provide expertise and infrastructure in the areas of oncology sales, marketing, and distribution. Assuming KTH-222 clinical trials confirm the Target Product Profile, Kalos has every expectation that the medication will be well received.

Outlook
Forecast 3 Billion $ franchises in 4 years post commercialization

- Program one: human cancers and their related co-morbidities. This set of applications of our discovery is designed to develop limited-toxic tumor stasis and an improved quality of life without using chemotherapy or radiation therapy
- Program Two: therapeutic approaches to retinal diseases. This use of our technology is based upon the cell signaling power of our therapeutic, which blocks VEGF signaling in wet Age related Macular Degeneration (AMD).
- Program Three: animal health and leverages the diuretic and therapeutic effects of ANP to replace Lasix which is being banned as a race day medication in Thoroughbred race horses and other competition horses.

Technology
- Kalos has particular knowledge of the mechanisms that limit and control cardiac remodeling under stress and expertise in the adaption of these systems related to tubulin disruption.

Human
- The company's current focus is to progress KTH-222 to IND and clinical proof of concept. The company perceives potential application of its technology as both combination and maintenance therapies for multiple cancers including pancreatic, ovarian and prostate cancer, including novel QoL assessments. Given the high symptom burden and potentially limited life expectancies of patients with pancreatic cancer, particularly those with advanced disease, the importance of measuring the impact of cancer treatment not only on survival, but also on patient QoL, is well recognized and needed.

Animal
- Kalos expects success containing metastatic disease and will be entering a HSA study in canines. Kalos has an animal health drug, KTV-111 for use in equines and companion animals.

Intellectual Property
- The company has been issued European Patent and filed WIPO PCT patent applications which claim ANP analog composition of matter, pharmaceutical composition and method of use as drug treatments for proliferative disorders and retinal disorders and disease.
- Prosecution of these patents and the filing of new inventions are ongoing. Kalos seeks to protect its intellectual property in countries throughout the world and has no knowledge of circumstances that would preclude grant of its patent applications.

Team
Kalos has assembled a team of experienced and industry recognized executives

- George Colberg
  CEO, Chairman and Founder
- Michael Kozlowski, OD, PhD Chief Science Officer
- James Merritt, M.D.
  Chief Medical Officer
- Jamie Jones
  Chief Business Officer

2020 Scheduled Trials
- KTH-222 Phase 1 will consist of an open label, conventional dose escalation, safety, pharmacokinetic and dose/schedule selection study, 48 patients with advanced pancreatic and/or ovarian cancer, with positive tumor markers and biopsy/imaging accessible lesions at two clinical sites.
- KTV-111 EIPH POC study formulated as a sterile solution drug product which will be nebulized employing a Nortev Flexineb prior to administration.

www.kalostherapeutics.com  info: gcolberg@kalostpx.com